SGLT6- 治疗肥胖的药物靶点？
SGLT6 - A pharmacological target for the treatment of obesity?
机构信息
a CardioMetabolic Diseases Research , Boehringer-Ingelheim Pharma GmbH & Co. KG , Biberach an der Riss , Germany.
b Medicinal Chemistry , Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany.
出版信息
Adipocyte. 2018;7(4):277-284. doi: 10.1080/21623945.2018.1516098. Epub 2018 Oct 11.
Abstract
Despite increased knowledge of nutrient intake regulation and energy homeostasis, treatment options for obesity remain limited. Food reward consists of two branches: gustatory and post-ingestive nutritive information. Drosophila lacking dSLC5A11 (sodium/glucose cotransporter 6-SGLT6) prefer L-glucose over D-glucose independently of their state of satiety. Human SGLT6 is an active transporter of myo-inositol and D-glucose. We investigated expression of SGLT6 in human tissue and found a significant expression in the small intestine and brain. The preference between a metabolizable and a non-metabolizable sugar was tested in 3 mouse models with a selective and potent SGLT6 inhibitor. No influence on sugar preference was seen with SGLT6 inhibition. These studies suggest that SGLT6 does not play a significant role in nutrient sensing in mammals.
摘要
尽管人们对营养摄入调节和能量平衡有了更多的了解，但肥胖的治疗选择仍然有限。食物奖励由两个分支组成：味觉和摄食后营养信息。缺乏 dSLC5A11（钠/葡萄糖协同转运蛋白 6-SGLT6）的果蝇在不考虑饱腹感的情况下，优先选择 L-葡萄糖而不是 D-葡萄糖。人类 SGLT6 是肌醇和 D-葡萄糖的活性转运蛋白。我们研究了 SGLT6 在人体组织中的表达，发现它在小肠和大脑中有明显的表达。在 3 种具有选择性和强效 SGLT6 抑制剂的小鼠模型中，测试了可代谢糖和不可代谢糖之间的偏好。SGLT6 抑制对糖偏好没有影响。这些研究表明，SGLT6 在哺乳动物的营养感应中不起重要作用。
相似文献
1
SGLT6 - A pharmacological target for the treatment of obesity?
Adipocyte. 2018;7(4):277-284. doi: 10.1080/21623945.2018.1516098. Epub 2018 Oct 11.
2
The transport mechanism of the human sodium/myo-inositol transporter 2 (SMIT2/SGLT6), a member of the LeuT structural family.
Am J Physiol Cell Physiol. 2014 Sep 1;307(5):C431-41. doi: 10.1152/ajpcell.00054.2014. Epub 2014 Jun 18.
3
Kinetics and specificity of the renal Na+/myo-inositol cotransporter expressed in Xenopus oocytes.
J Membr Biol. 1995 Jan;143(2):103-13. doi: 10.1007/BF00234656.
4
Osmoregulatory inositol transporter SMIT1 modulates electrical activity by adjusting PI(4,5)P2 levels.
Proc Natl Acad Sci U S A. 2016 Jun 7;113(23):E3290-9. doi: 10.1073/pnas.1606348113. Epub 2016 May 23.
5
Functional studies of a chimeric protein containing portions of the Na(+)/glucose and Na(+)/myo-inositol cotransporters.
Biochim Biophys Acta. 2000 Jun 1;1466(1-2):139-50. doi: 10.1016/s0005-2736(00)00186-3.
6
Osmoregulatory alterations in myo-inositol uptake by bovine lens epithelial cells. Part 4: Induction pattern of Na(+)-myo-inositol cotransporter mRNA under hypertonic conditions denoting an early-onset, interactive, protective mechanism against water stress.
Invest Ophthalmol Vis Sci. 1994 Nov;35(12):4118-25.
7
Characterization of the expression and regulation of genes necessary for myo-inositol biosynthesis and transport in the seminiferous epithelium.
Biol Reprod. 2004 Mar;70(3):744-51. doi: 10.1095/biolreprod.103.022731. Epub 2003 Nov 12.
8
Osmoregulatory alterations in myo-inositol uptake by bovine lens epithelial cells. Part 2: Cloning of a 626 bp cDNA portion of a Na+/myo-inositol cotransporter, an osmotic shock protein.
Invest Ophthalmol Vis Sci. 1994 Mar;35(3):1236-42.
9
Acute anti-obesity effects of intracerebroventricular 11β-HSD1 inhibitor administration in diet-induced obese mice.
J Neuroendocrinol. 2018 Mar;30(3):e12580. doi: 10.1111/jne.12580.
10
A novel GIP analogue, ZP4165, enhances glucagon-like peptide-1-induced body weight loss and improves glycaemic control in rodents.
Diabetes Obes Metab. 2018 Jan;20(1):60-68. doi: 10.1111/dom.13034. Epub 2017 Jul 27.
引用本文的文献
1
High-Fructose-Induced Salt-Sensitive Hypertension: The Potential Benefit of SGLT4 or SGLT5 Modulation.
Nutrients. 2025 Jul 30;17(15):2511. doi: 10.3390/nu17152511.
2
SGLT2 Inhibitors: From Structure-Effect Relationship to Pharmacological Response.
Int J Mol Sci. 2025 Jul 19;26(14):6937. doi: 10.3390/ijms26146937.
3
Sotagliflozin: Two Birds with One Stone?
Cardiovasc Drugs Ther. 2025 Jun 4. doi: 10.1007/s10557-025-07723-z.
4
The impact of solute carrier proteins on disrupting substance regulation in metabolic disorders: insights and clinical applications.
Front Pharmacol. 2025 Jan 9;15:1510080. doi: 10.3389/fphar.2024.1510080. eCollection 2024.
5
Renal Sugar Metabolites and mRNA Expression of Glucose Transporters in Meat-Type Chickens with Differing Residual Water Intake.
Animals (Basel). 2024 Oct 9;14(19):2912. doi: 10.3390/ani14192912.
6
Envisioning Glucose Transporters (GLUTs and SGLTs) as Novel Intervention against Cancer: Drug Discovery Perspective and Targeting Approach.
Curr Drug Targets. 2025;26(2):109-131. doi: 10.2174/0113894501335877240926101134.
7
Neurodevelopment Is Dependent on Maternal Diet: Placenta and Brain Glucose Transporters GLUT1 and GLUT3.
Nutrients. 2024 Jul 21;16(14):2363. doi: 10.3390/nu16142363.
8
Glucose appetition in C57BL/6J mice: Influence of nonnutritive sweetener experience, food deprivation state and sex differences.
Physiol Behav. 2024 Sep 1;283:114596. doi: 10.1016/j.physbeh.2024.114596. Epub 2024 May 28.
9
The relationship between SGLT2 and systemic blood pressure regulation.
Hypertens Res. 2024 Aug;47(8):2094-2103. doi: 10.1038/s41440-024-01723-6. Epub 2024 May 23.
10
Bridging the gap: glucose transporters, Alzheimer's, and future therapeutic prospects.
Front Cell Dev Biol. 2024 Jan 16;12:1344039. doi: 10.3389/fcell.2024.1344039. eCollection 2024.
本文引用的文献
1
Treatment with HC-070, a potent inhibitor of TRPC4 and TRPC5, leads to anxiolytic and antidepressant effects in mice.
PLoS One. 2018 Jan 31;13(1):e0191225. doi: 10.1371/journal.pone.0191225. eCollection 2018.
2
Quantification of Transporter and Receptor Proteins in Dog Brain Capillaries and Choroid Plexus: Relevance for the Distribution in Brain and CSF of Selected BCRP and P-gp Substrates.
Mol Pharm. 2017 Oct 2;14(10):3436-3447. doi: 10.1021/acs.molpharmaceut.7b00449. Epub 2017 Sep 19.
3
pH-dependent solubility and permeability profiles: A useful tool for prediction of oral bioavailability.
Eur J Pharm Sci. 2017 Jul 15;105:82-90. doi: 10.1016/j.ejps.2017.04.016. Epub 2017 May 3.
4
Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants.
Lancet. 2016 Apr 2;387(10026):1377-1396. doi: 10.1016/S0140-6736(16)30054-X.
5
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720. Epub 2015 Sep 17.
6
Postoral glucose sensing, not caloric content, determines sugar reward in C57BL/6J mice.
Chem Senses. 2015 May;40(4):245-58. doi: 10.1093/chemse/bjv002. Epub 2015 Feb 24.
7
Hypothalamic melanin concentrating hormone neurons communicate the nutrient value of sugar.
Elife. 2013 Dec 31;2:e01462. doi: 10.7554/eLife.01462.
8
In vitro P-glycoprotein efflux ratio can predict the in vivo brain penetration regardless of biopharmaceutics drug disposition classification system class.
Drug Metab Dispos. 2013 Dec;41(12):2012-7. doi: 10.1124/dmd.113.053868. Epub 2013 Sep 5.
9
Taste-independent nutrient selection is mediated by a brain-specific Na+ /solute co-transporter in Drosophila.
Nat Neurosci. 2013 May;16(5):526-8. doi: 10.1038/nn.3372. Epub 2013 Mar 31.
10
Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus.
Am J Physiol Renal Physiol. 2013 Jan 15;304(2):F156-67. doi: 10.1152/ajprenal.00409.2012. Epub 2012 Nov 14.
Zotero 插件